Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

Cerenome sets sights on 2027 randomised trial after small early REYOBIQ safety dataset

Early data from ten patients give Cerenome a first case for taking its radiotherapy REYOBIQ into a randomised study next year, though the product has no commercial path yet.

16 Nov 2026 · Cerenome, Inc. CNSY · Company news

Cerenome, Inc. has put a first set of human data behind its plan for a randomised mid-stage trial of REYOBIQ (rhenium Re186 obisbemeda), an investigational radiotherapy delivered into the brain's fluid spaces for patients whose solid-tumour cancers have spread to the leptomeninges. The company announced the results on 16 November 2026. They were shown as a poster at the Society for Neuro-Oncology annual meeting three days earlier.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Cerenome, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →